138 related articles for article (PubMed ID: 8205048)
1. [The antithrombotic action of a protein C activator from the venom of Agkistrodon blomhoffi ussuriensis in thrombus formation in an extracorporeal shunt in rats].
Kogan AE; Bashkov GV; Bobruskin ID; Romanova EP; Makarov VA; Strukova SM
Eksp Klin Farmakol; 1994; 57(2):42-5. PubMed ID: 8205048
[TBL] [Abstract][Full Text] [Related]
2. Protein C activator from the venom of Agkistrodon blomhoffi ussuriensis retards thrombus formation in the arterio-venous shunt in rats.
Kogan AE; Bashkov GV; Bobruskin ID; Romanova EP; Makarov VA; Strukova SM
Thromb Res; 1993 Jun; 70(5):385-93. PubMed ID: 8378894
[TBL] [Abstract][Full Text] [Related]
3. Thrombolysis effect with FIIa from Agkistrodon acutus venom in different thrombosis model.
Chen JH; Liang XX; Qiu PX; Yan GM
Acta Pharmacol Sin; 2001 May; 22(5):420-2. PubMed ID: 11743889
[TBL] [Abstract][Full Text] [Related]
4. [Antithrombotic effect of protein C activator from a snake venom].
Strukova SM; Kogan AE; Tara AA; Aaviksaar AA
Vopr Med Khim; 1989; 35(5):115-9. PubMed ID: 2617927
[TBL] [Abstract][Full Text] [Related]
5. Genetic strain differences in platelet aggregation and thrombus formation of laboratory rats.
Sudo T; Ito H; Hayashi H; Nagamura Y; Toga K; Yamada Y
Thromb Haemost; 2007 Apr; 97(4):665-72. PubMed ID: 17393031
[TBL] [Abstract][Full Text] [Related]
6. The effect of fibrinolytic enzyme FIIa from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits.
Lin X; Liang XX; Chen JS; Chen Q; Qiu PX; Yan GM
Transl Res; 2007 Nov; 150(5):295-302. PubMed ID: 17964518
[TBL] [Abstract][Full Text] [Related]
7. The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests.
Krupiński K; Ferber H; Breddin HK; Bielawiec M
Acta Haematol Pol; 1994; 25(3):235-42. PubMed ID: 7992596
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis.
Ono M; Nawa K; Marumoto Y
Thromb Haemost; 1994 Sep; 72(3):421-5. PubMed ID: 7855794
[TBL] [Abstract][Full Text] [Related]
9. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
10. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
[TBL] [Abstract][Full Text] [Related]
12. Effects of antithrombotic agents evaluated in a nonhuman primate vascular shunt model.
Mason RG; Wolf RH; Zucker WH; Shinoda BA; Mohammad SF
Am J Pathol; 1976 Jun; 83(3):557-68. PubMed ID: 820202
[TBL] [Abstract][Full Text] [Related]
13. A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist.
Wang WJ; Huang TF
Thromb Haemost; 2001 Oct; 86(4):1077-86. PubMed ID: 11686327
[TBL] [Abstract][Full Text] [Related]
14. [Research on the protein C-activating property and influencial factors of protein C activator isolated from the venom of Agkistrodon halys].
Hou L; Zhao L; Zhao Z; Huang S; He Q; Kong T; Guan J
Zhong Yao Cai; 2005 Mar; 28(3):198-201. PubMed ID: 16107029
[TBL] [Abstract][Full Text] [Related]
15. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis.
Bagdy D; Szabó G; Barabás E; Bajusz S
Thromb Haemost; 1992 Aug; 68(2):125-9. PubMed ID: 1412156
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-platelet aggregation tripeptide from Agkistrodon acutus venom: isolation and characterization.
Kong Y; Huo JL; Xu W; Xiong J; Li YM; Wu WT
Toxicon; 2009 Aug; 54(2):103-9. PubMed ID: 19345702
[TBL] [Abstract][Full Text] [Related]
18. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
19. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
[TBL] [Abstract][Full Text] [Related]
20. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
